Alto Neuroscience Novartis 35M ALTO-100 Depression

Alto Neuroscience announced the closing of a $35 million Series B financing, with participation from Novartis Pharma and other investors. This round brings Alto’s total funding to $75 million to date, and they will use the proceeds from the financing to advance lead candidates into Phase 2b studies in major depressive disorder in addition to continued development on other programs within its clinical-stage precision psychiatry pipeline.